Cantargia receives positive EMA opinion for orphan designation of nadunolimab for treatment of pancreatic cancer
Cantargia AB today announced that the Committee for Orphan Medicinal Products (COMP) at the European Medicines Agency (EMA) has issued a positive opinion for orphan designation of nadunolimab (CAN04) for treatment of pancreatic cancer. The European Commission is now expected to grant the orphan designation. This provides a range of incentives in the continued clinical development of CAN04 in pancreatic cancer.The interleukin-1 receptor accessory protein (IL1RAP)-binding antibody CAN04 is Cantargia’s lead program and is investigated in multiple clinical trials evaluating combination with